Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ze, E. | - |
dc.contributor.author | Baek, E.K. | - |
dc.contributor.author | Lee, J.J. | - |
dc.contributor.author | Chung, H.W. | - |
dc.contributor.author | Ahn, D.G. | - |
dc.contributor.author | Cho, H.J. | - |
dc.contributor.author | Kwon, J.C. | - |
dc.contributor.author | Kim, H.J. | - |
dc.contributor.author | Lee, H. | - |
dc.date.available | 2019-03-09T00:41:15Z | - |
dc.date.issued | 2014-09 | - |
dc.identifier.issn | 2287-285X | - |
dc.identifier.issn | 2287-285X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/13896 | - |
dc.description.abstract | BACKGROUND/AIMS: Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB). However, the long-term outcomes of LAM+ADV and 1-mg entecavir (ETV) rescue therapies have still been limited. The aim of this study was to determine the long-term outcomes of these two rescue therapies.METHODS: Sixty patients with LAM-r CHB underwent rescue therapy with LAM+ADV (n=36) or 1-mg ETV (n=24). We determined the duration of rescue therapy, timing and type of mutation, undetectable serum hepatitis B virus (HBV) DNA by PCR (lower limitation of detection, < 140 copies/mL), biochemical response (alanine aminotransferase < 40 IU/mL), and the incidence of hepatitis B virus e antigen (HBeAg) seroconversion and virologic breakthrough.RESULTS: Baseline characteristics did not differ between the two therapy groups. The duration of rescue therapy was 56 months (range, 14-100 months) in the ADV+LAM group and 42 months (range, 12-73 months) in the ETV group (P=0.036). The cumulative rates of HBV DNA undetectability and HBeAg seroconversion up to 6 years were 88.6% and 43.0%, respectively, in the ADV+LAM group, and 45.8% and 31.8% in the ETV group. The rate of virologic breakthrough and resistance was 14.4% in the ADV+LAM group and 71.9% in the ETV group (P=0.001).CONCLUSIONS: Combination of LAM and ADV therapy for up to 6 years achieved modest rates of virological suppression and resistance. ETV is not an optimal therapy because the risk of viral breakthrough to ETV increases over time. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한간학회 | - |
dc.title | Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir | - |
dc.title.alternative | Long-term outcomes of two rescue therapies in lamivudine- refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir | - |
dc.type | Article | - |
dc.identifier.doi | 10.3350/cmh.2014.20.3.267 | - |
dc.identifier.bibliographicCitation | Clinical and molecular hepatology, v.20, no.3, pp 267 - 273 | - |
dc.identifier.kciid | ART001920532 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-84932104604 | - |
dc.citation.endPage | 273 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 267 | - |
dc.citation.title | Clinical and molecular hepatology | - |
dc.citation.volume | 20 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Adefovir | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | Entecavir | - |
dc.subject.keywordAuthor | Lamivudine | - |
dc.subject.keywordAuthor | Resistance | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.